Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies

AIMS: Lenalidomide is an immunomodulatory imide drug used broadly in the treatment of multiple myeloma and lymphoma. It continues to be evaluated in chronic lymphocytic leukaemia (CLL) at lower doses due to dose‐related toxicities including tumour flare and tumour lysis syndrome. This study aimed to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Hughes, Jim H., Phelps, Mitch A., Upton, Richard N., Reuter, Stephanie E., Gao, Yue, Byrd, John C., Grever, Michael R., Hofmeister, Craig C., Marcucci, Guido, Blum, William, Blum, Kristie A., Foster, David J.R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475687/
https://ncbi.nlm.nih.gov/pubmed/30672004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13873
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados